Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1193 • ACR Convergence 2020
Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
Maria Luque-Tevar¹, Carlos Pérez-Sánchez¹, Pilar Font², Alejandra Maria Patiño-Trives¹, Montserrat Romero-Gomez², Desirée Ruiz-Vilchez², Sara Remuzgo-Martínez³, Raquel López-Mejías⁴, Iván Arias de la Rosa¹, Carmen Torres-Granados¹, María-Carmen Abalos-Aguilera¹, Rafaela Ortega-Castro², Alejandro Escudero-Contreras², Carlos Rodriguez-Escalera⁵, Jose Perez-Venegas⁶, Mª Dolores Ruiz-Montesinos⁶, Carmen Dominguez⁶, Carmen Romero-Barco⁷, Antonio Fernandez-Nebro⁸, Natalia Mena-Vazquez⁹, Jose Luis Marenco¹⁰, Julia Uceda-Montañez¹⁰, Mª Dolores Toledo-Coello¹¹, Nuria Barbarroja¹, M Angeles Aguirre², Eduardo Collantes², Miguel A Gonzalez-Gay¹² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario de Jaen, Jaén, Spain, ⁶Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, ⁷Hospital Clínico Universitario, Málaga, Málaga, Spain, ⁸University of Malaga, Malaga, Spain, ⁹Hospital Regional Universitario de Málaga, Málaga, Spain, ¹⁰Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹¹Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, ¹²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander
Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
Abstract Number: 1209 • ACR Convergence 2020
The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w
Shuntaro Saito¹, Katsuya Suzuki², Keiko Yoshimoto², Yasushi Kondo², Jun Kikuchi², Kotaro Otomo², Hironari Hanaoka², Yuko Kaneko² and Tsutomu Takeuchi³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Interleukin-6 (IL-6) is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) and Sarilumab (SAR) are monoclonal antibodies that bind to…
Abstract Number: 1226 • ACR Convergence 2020
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Roxanne Cooksey¹, Sinead Brophy¹, Muhammad Azizur¹, Jonathan Kennedy¹ and Ernest Choy², ¹Swansea University, Swansea, Wales, United Kingdom, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics. Etanercept biosimilar,…
Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Ching-Huang Ho¹, Andrea Silva¹ and I-Cheng Ho², ¹Brigham and Women's Hospital, Boston, MA, ²Birgham and Women's Hospital, Boston, MA
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Patricia Castro Pérez¹, Alberto Onteniente González¹, Angel Aragón Díez¹, Angel Gallegos Cid¹, Jesús Garcia-Arroba Muñoz¹ and Jose Manuel Rodriguez heredia¹, ¹Hospital de Getafe, Madrid, Spain
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…
Abstract Number: 1551 • ACR Convergence 2020
Rapid Effect of Tofacitinib in Reducing US Joint and Tendon Inflammatory Lesions of RA Patients: Data from a 24 Weeks Longitudinal Study
Giuseppe Germanò¹, Pierluigi Macchioni², Giovanni Ciancio³, Filippo Crescentini¹, Andrea Caruso², Beatrice Maranini⁴, Sara Bonazza⁴, Gilda Sandri⁵, Maria Teresa Mascia⁵, Govoni Marcello⁴ and Carlo Salvarani⁶, ¹Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Emilia-Romagna, Italy, ²Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Italy, ³Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Emilia-Romagna, Italy, ⁴Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Italy, ⁵Struttura Complessa di Reumatologia- Università di Modena e Reggio Emilia- Policlinico di Modena, Modena, Italy, ⁶Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To explore the effects of tofacitinib (Tofa) on US lesions in a consecutive series of patients with active RA MTX and/or bioDMARDs -IR. Methods: In…
Abstract Number: 1707 • ACR Convergence 2020
Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis
Richard Martin¹, Marianna Shershneva² and Lily Zurkovsky³, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Senior Administrative Program Specialist, Office of Continuing Professional Development University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Forefront Collaborative, Carmel, IN
Background/Purpose: A core CMS policy goal is to improve patient experience by encouraging patient-centered care and shared decision making (SDM). However, SDM techniques are underutilized…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 1745 • ACR Convergence 2020
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
Rieke Alten¹, Claire Behar², Christine Boileau², Pierre Merckaert², Ebenezer Afari², Virginie Vannier-Moreau³, Sean Connolly³, Yedid Elbez², Pierre-Antoine Juge⁴ and Karissa Lozenski³, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Excelya, Boulogne-Billancourt, France, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
Background/Purpose: In the ACTION (NCT02109666) study, using multivariable Cox proportional hazards regression models, patient (pt) global assessment of pain, country, reason for stopping last biologic,…
Abstract Number: 1762 • ACR Convergence 2020
Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
Alvin Wells¹, Kirstin Griffing², Amanda Quebe², Luna Sun², Hong Zhang³ and Paulo Reis², ¹Aurora Rheumatology and Immunotherapy Center, Franklin, ²Eli Lilly and Company, Indianapolis, IN, ³Tech Data Services, King of Prussia, PA
Background/Purpose: In clinical practice, drug treatment decisions must account for the expected benefit from a drug along with its potential risks. Evaluating the number needed…
Abstract Number: 1970 • ACR Convergence 2020
Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model
Alexandra Damerau¹, Moritz Pfeiffenberger¹, Annemarie Lang¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine, Berlin, Germany
Background/Purpose: Our ultimate goal is to study potential drug candidates in an experimental setting of arthritis. Therefore, we aim to develop a human in vitro…
Abstract Number: 2005 • ACR Convergence 2020
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby², Giovanni Giorli², Alessandra Nerviani¹, Rebecca Hands², Liliane Fossati-Jimack², Georgina Thorborn², Myles Lewis¹ and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
Abstract Number: 0030 • ACR Convergence 2020
Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells
Rizi Ai¹, Gary Firestein², David Boyle³ and Wei Wang⁴, ¹University of California San Diego, San Diego, CA, ²University of California, San Diego, La Jolla, CA, ³UCSD, La Jolla, CA, ⁴UCSD, La Jolla
Background/Purpose: To understand the epigenetic patterns of T cells accumulated in rheumatoid arthritis (RA) synovium, we characterized DNA methylation of CD3+ T cells in peripheral…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
Abstract Number: 0147 • ACR Convergence 2020
The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
Peter Taylor¹, Robin Dore², Kate Williams³, Sarah Acaster³, Jenya Antonova⁴ and Mark Genovese⁵, ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Private practice, Tustin, CA, ³Acaster Lloyd Consulting, London, United Kingdom, ⁴Gilead Sciences, Foster City, CA, ⁵Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The importance of patient-relevant outcomes, such as pain, fatigue and physical functioning, has been long established in the field of rheumatoid arthritis (RA). Patient-reported…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].